Is vigabatrin the same as the vigabatrin in Vigabatrin

Vigabatrin is the common name of Vigabatrin (Sabril). The two are completely consistent in pharmacological effects, chemical composition and clinical uses. Vigabatrin is the trade name drug first developed by Sanofi and marketed in many countries, while vigabatrin is the standard name for its active pharmaceutical ingredient. Whether in the FDA or EMA registration information in European and American countries or in domestic drug registration information, Vigabatrin refers to the same molecular structure, that is, an irreversible inhibitor of gamma-aminobutyric acid (GABA) aminotransferase. It blocks the GABA degrading enzyme X-amino acid transaminase, thereby increasing the concentration of GABA in the brain, inhibiting abnormal neuron discharge, and achieving anti-epileptic effects.

In clinical practice, whether patients are using the original drug labeled as "Vibatrin" or a generic drug with the generic name "vigabatrin" approved for marketing in some regions, the treatment mechanism, dosage recommendations, scope of indications and potential adverse reactions are the same. For example, it is used to treat refractory complex focal epilepsy (CPS) and infantile spasms (IS), especially when other antiepileptic drugs are ineffective or ineffective, Vigabatrin is regarded as an important supplementary regimen.

It should be pointed out that although the ingredients are the same, drugs produced by different manufacturers may have slight differences in excipient ratio, bioavailability, price and packaging specifications. These factors may have a certain impact on the patient's medication experience and blood concentration. However, the clinical effects of generic drugs that have undergone strict bioequivalence evaluation and have been approved by the drug regulatory agency are considered to be equivalent to the original drugs.

Therefore, vigabatrin is the name of the active ingredient in Vigabatrin, and there is essentially no difference between the two in medical practice. When prescribing, doctors can choose to indicate the generic name or trade name depending on the region. Patients should confirm the source and description of the drug with their doctor or pharmacist before taking the medicine to ensure continuity and safety of treatment. For epilepsy patients who need to use this drug for a long time, they should also cooperate with regular vision examinations, because Vigabatrin has the risk of causing visual field defects, which is one of the most important adverse reactions when using this drug.

Reference materials:https://www.sabril.net/